Scientists have developed a DNA nanoflower that delivers chemotherapy and gene therapy directly to breast cancer cells, boosting effectiveness while reducing side effects in early tests.
Breast cancer continues to be one of the most prevalent cancers worldwide. Although drugs like Doxorubicin (DOX) are commonly used, their effectiveness is often limited by toxicity, poor targeting, and the development of multi-drug resistance. DNA nanostructures, due to their biocompatibility and programmability, are gaining attention as more precise delivery vehicles.
Researchers have created a new DNA nanoflower-based drug delivery system capable of co-delivering an antisense oligonucleotide (ASO) and the chemotherapy drug DOX.
Published in Micro & Nano Letters, the study demonstrates how they used a dual amplification method to form a flower-shaped DNA nanostructure with a high drug-loading capacity and highly targeted delivery.
This study focuses on tackling the limitations of traditional DOX-based therapies by combining gene silencing and chemotherapy into one delivery system. The DNA nanoflowers are also functionalised with AS1411, an aptamer that binds to nucleolin (a protein overexpressed on many tumour cells), improving targeting accuracy.
Building the DNA Nanoflower
The research team used a two-step amplification process to construct the nanoflowers. First, they used rolling circle amplification with Phi29 DNA polymerase to produce long single-stranded DNA sequences with repeating units. These sequences were then further amplified using multiplexed enzyme amplification, forming the unique nanoflower structure.
Specific sequences were engineered into the DNA scaffold to carry both the ASO and DOX drugs. ASO targeted PLK1, a gene associated with cancer cell growth and division, while DOX was intercalated directly into the DNA structure, making use of its natural affinity for DNA bases.
The AS1411 aptamer was conjugated to the nanostructure to enable tumour-specific targeting. The team confirmed the structure’s size, morphology, and successful functionalisation using a range of analytical techniques, including transmission electron microscopy, dynamic light scattering, and gel electrophoresis.
In Vitro and In Vivo Testing
In vitro experiments were carried out using MCF-7 breast cancer cells to assess cellular uptake, gene silencing, cytotoxicity, apoptosis, and cell migration. The researchers used flow cytometry, CCK-8 assays, qRT-PCR, western blotting, and Transwell migration assays to evaluate these parameters.
The in vivo phase of the study used nude mice implanted with MCF-7 cells to form breast tumours. Once tumours had developed, mice were treated locally with the nanoflower formulations.
Promising Results in Early Tests
Analysis of the DNA nanoflowers showed their high drug-loading efficiency and their uniform, flower-like shape. The aptamer-functionalised structures showed significantly enhanced uptake in cancer cells compared to non-targeted controls.
In lab tests, the nanoflower carrying both ASO and DOX (referred to as DNF-ASO@DOX) reduced tumour cell proliferation and triggered apoptosis more effectively than either DOX or ASO alone. The ASO silenced PLK1 expression, confirmed at both the mRNA and protein levels, and resulted in cell cycle arrest and increased cell death.
The system allowed for controlled drug release in response to enzymatic signals, specifically FEN1, which is overexpressed in tumour cells. This meant the active agents were mainly released at the tumour site, minimising damage to healthy tissue.
In animal studies, tumours treated with DNF-ASO@DOX showed markedly reduced growth. Tissue analysis revealed higher levels of apoptosis and lower PLK1 expression in tumour cells. Blood tests and organ inspections indicated minimal systemic toxicity, supporting the biocompatibility of the nanoflower platform.
Looking Ahead
The study highlights the potential of DNA nanoflowers as a new kind of combination therapy tool, able to deliver both genetic and chemotherapeutic treatments in a highly targeted way. With its tumour-specific binding and controlled release mechanisms, the platform could offer a new route to overcome issues like multi-drug resistance and off-target side effects that currently limit breast cancer treatments.
Journal Reference
Shen X., Zhu A., et al. (2025). DNA Nanoflower Enables Controlled Co-Delivery of Antisense Oligodeoxynucleotide and Doxorubicin for Anti-Breast Cancer Treatment. Micro & Nano Letters. DOI: 10.1002/mnnl.202500008, https://ietresearch.onlinelibrary.wiley.com/doi/10.1049/mna2.70008
News
Cutting Two Amino Acids Slowed Prostate Cancer in Mice
A newly identified link between amino acid metabolism and cholesterol production may help prostate tumors adapt to hormone therapy. Prostate cancer can find ways around treatments designed to deprive tumors of the hormones they [...]
Largest-Ever Physics Survey Raises New Doubts About Our Model of the Universe
Physicists around the world remain deeply divided on key mysteries of the universe, from dark matter to quantum gravity. The standard cosmological model failed to gain majority support, and no leading theory dominated the [...]
Scientists Just Overturned a 100-Year-Old Belief About Bacteria in the Lungs
New findings raise questions about the role of microbes living in the lungs. More than 35 trillion bacteria live throughout the human body, forming microbiomes in the gut, mouth, lungs, skin, and urogenital tract. [...]
GHCE Concept
From the preface of the book Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artificial Intelligence, Edited by Frank Boehm: Since the publication of my first book (Nanomedical Device and Systems [...]
Novartis, Ionis drug failure spurs questions
Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a result with important implications for cardiovascular drug research. Dive Brief: An RNA drug from [...]
New injectable treatment helps the brain rebuild after stroke
Biomedical engineers at Duke University have created an injectable biomaterial that may help the brain recover from damage left behind by an ischemic stroke. In experiments with mice, the material transformed the cavity created [...]
Scientists Discover a Hidden “Immune Organ” Inside the Skull
Researchers discovered lymph node-like immune hubs inside skull bone marrow that appear to act as rapid-response centers for the brain. For decades, the brain was thought to operate largely apart from the immune system. [...]
Engineered tRNAs and lipid nanoparticles target nonsense mutation cystic fibrosis
Researchers have developed a potential new approach for treating a form of cystic fibrosis caused by so-called nonsense mutations, combining chemically modified transfer RNAs with lipid nanoparticles designed to deliver the therapy directly to [...]
New pancreatic cancer drug carries a $39,800 monthly list price
A groundbreaking treatment for one of the most common forms of pancreatic cancer has been approved in pill form by the FDA. Revolution Medicines’ oral tablet daraxonrasib, branded as Rasonque, reduced the risk of [...]
Researchers Have Discovered a New Way To Reduce Chronic Nerve Pain
A cancer-linked protein called BRAF may help drive chronic nerve pain, and existing cancer drugs targeting it reduced pain sensitivity in preclinical models. Chronic nerve pain can persist long after an injury and often [...]
Our books now available worldwide!
Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]
Quantum-Enabled Regenerative Health: Reimagining Wellness, Precision Health and Longevity Medicine
Introduction Healthcare is approaching a frontier where the quantum portfolio could influence not only how disease is diagnosed and treated, but how health itself is measured, modeled, predicted and preserved. Quantum computing, quantum simulation, [...]
FDA Clears First-of-Its-Kind Nonmedication Treatment for PTSD
The FDA has cleared a system that uses brain activity data to personalize magnetic stimulation for PTSD, adding a new nonmedication treatment option. Every day in the United States, approximately 17.5 veterans die by suicide, [...]
FDA approves breakthrough drug to treat advanced pancreatic cancer
The Food and Drug Administration (FDA) approved on Wednesday a drug that could extend the survival of those with metastatic pancreatic cancer. The drug, called daraxonrasib, will be sold under the brand name Rasonque [...]
AI Decodes a Hidden DNA Signal Linked to Disease-Causing Mutations
Machine learning identifies the likely “initiator” and enables new predictions about DNA mutations that can cause disease. Every human cell depends on tens of thousands of genes being switched on at the right time [...]
Pope Leo Urges Global Response to Congo’s Deadliest Ebola Outbreak
Pope Leo called for international action to address the Ebola outbreak in the Democratic Republic of Congo. The epidemic has claimed over 2,500 lives and is the nation's largest recorded outbreak. The Pope emphasized [...]
